Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announced today that PM360, a
publication for marketing decision makers in the pharmaceutical,
biotech, diagnostics and medical device industries, has awarded the
previously nominated Ameluz® marketing campaign, created by
Biofrontera Inc. along with Elevate Healthcare,
“Relaunch/Revitalization of the Year” and “Professional
Website/Online Initiative of the Year” awards. These awards were
announced at the 14th Annual Trailblazer Awards held September 22,
2022 in New York, where they also recognized the previously
announced Trailblazer Brand Champion in Dermatology, Leslie
Hopkins, Associate Director of Marketing at Biofrontera Inc. The
winners will be featured in the October issue of PM360 and on
www.pm360online.com.
Biofrontera’s Ameluz® marketing campaign,
developed in collaboration with the healthcare-focused branding
agency Elevate Healthcare Marketing, was a creative call to action
emphasizing the threat of actinic keratoses (AK). Titled “Danger
Lurks Below the Surface,” the campaign featured images of sharks
and aims to create awareness of the danger associated with visible
and invisible AKs. It also positions Ameluz® plus BF-RhodoLED®
(Ameluz-PDT) as the only photodynamic therapy (PDT) with an
approval for field treatment that enables healthcare professionals
to protect patients against the risks posed by fields of
premalignant AKs.
“We’re very proud of our marketing team and the
collaboration with Elevate Healthcare. Their efforts are not only
recognized by the marketing industry but also are reflected in the
improved revenue we’re generating. The launch of the Ameluz website
was a strategic step in a broader initiative to enhance medical
support and build brand awareness. Educating the industry on the
importance of field therapy and the efficacy of our products is a
critical component of our market expansion and commercial strategy
that we believe will increase utilization of PDT, especially among
patients with 15 or more AK lesions,” stated Erica Monaco, Chief
Executive Officer of Biofrontera Inc.
“Leslie has also been a true brand champion not
only for PM360 but also for us, having led the team in the relaunch
of the Ameluz campaign. She inspired re-thinking the AK treatment
landscape, challenged perceptions of PDT, and pushed for a stronger
creative vision for the campaign to disrupt the market and
reinvigorate the brand,” added Mark Baldyga, Vice President of
Sales & Marketing at Biofrontera Inc.
Since 2009, the PM360 Trailblazer Awards have
recognized outstanding achievement and innovation in healthcare
marketing. Each year, nominations are judged by the PM360 Editorial
Advisory Board, a distinguished cross-section of industry experts.
Initiatives are selected in 16 distinct categories. Both Silver and
Gold winners were selected in each category for their ability to
stand out in the complex, ever-changing healthcare environment, and
were judged on content, format, success in reaching the targeted
audience, and overall quality.
“Marketers increasingly face new challenges to
reach their audiences with messages that resonate, whether that is
an oversaturated market, rising consumer expectations, or even a
worldwide pandemic,” says Anna Stashower, CEO and Publisher of
PM360. “But each of our Initiative Award winners are a prime
example of how to overcome those challenges through creativity,
ingenuity, and a willingness to better understand healthcare
professionals, patients, and payers to better deliver an experience
that matches their wants and needs.”
The Ameluz marketing campaign has also been
previously recognized by other publications including earning a
Gold 2022 Award of Excellence from The Communicator Awards, a
leading international industry-agnostic awards program recognizing
excellence in communication, championing effective and meaningful
work.
About
PM360
PM360 is the premier, must-read magazine for
marketing decision makers in the pharmaceutical, biotech,
diagnostics and medical device industries. Published monthly, PM360
is the only journal that focuses on delivering the full spectrum of
practical information necessary for product managers and
pharmaceutical marketing professionals to succeed in the complex
and highly regulated healthcare environment.
The journal’s targeted and insightful editorial
focuses on issues that directly impact critical decision making,
including planning and implementation of cutting-edge strategies,
trends, the latest technological advances, branding/marketing,
advertising/promotion, patient/professional education, sales,
market research, PR and leadership. Additionally, the “360” in the
title signifies the span of this critical, how-to info with
personal and career insights for an enjoyable and thought-provoking
read.
By providing the full circle of enriching
content, PM360 is truly an indispensable tool for busy and
productive marketing professionals to stay at the top of their
game.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Jul 2023 to Jul 2024